Antibody-Drug Conjugates by Laurent DucryAntibody-Drug Conjugates by Laurent Ducry

Antibody-Drug Conjugates

byLaurent Ducry

Hardcover | August 3, 2013

Pricing and Purchase Info


Earn 1,035 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs.  In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion.  Written in the highly successful Methods in Molecular BiologyT format, these detailed chapters include the kind of practical implementation advice that guarantees quality results.


Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.
Title:Antibody-Drug ConjugatesFormat:HardcoverDimensions:317 pagesPublished:August 3, 2013Publisher:Springer-Verlag/Sci-Tech/TradeLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:1627035400

ISBN - 13:9781627035408

Look for similar items by category:


Table of Contents

1. Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review

            Ingrid Sassoon and Véronique Blanc


2. Antibody-Drug Conjugate Target Selection: Critical Factors

            Neil H. Bander


3. Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization

            Jay Harper, Shenlan Mao, Patrick Strout, and Adeela Kamal


4. Antibody-Drug Conjugate Payloads

            Jan Anderl, Heinz Faulstich, Torsten Hechler and Michael Kulke


5. Linker Technologies for Antibody-Drug Conjugates

            Birte Nolting


6. In Vivo Testing of Drug-Linker Stability

            Pierre-Yves Abecassis and Céline Amara


7. Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates

            Kedan Lin, Jay Tibbitts, and Ben-Quan Shen


8. Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment

            Miriam I. Hensgen and Bernhard Stump


9. Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting

            James E. Stefano, Michelle Busch, Lihui Hou, Anna Park, and Diego A. Gianolio


10. Protocols for Lysine Conjugation

            Marie-Priscille Brun and Laurence Gauzy-Lazo


11. Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers

            Sunil Bhakta, Helga Raab, and Jagath R. Junutula


12. Enzymatic Antibody Modification by Bacterial Transglutaminase

            Patrick Dennler, Roger Schibli, and Eliane Fischer


13. Formulation Development of Antibody-Drug Conjugates

            William J. Galush and Aditya A. Wakankar


14. Conjugation Process Development and Scale-Up

            Bernhard Stump and Jessica Steinmann


15. Methods for Conjugating Antibodies to Nanocarriers

            Anil Wagh and Benedict Law


16. Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy

            Yan Chen


17. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High Performance Liquid Chromatography

            Jun Ouyang


18. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS

            Louisette Basa


19. Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF

            Joyce Lin and Alexandru C. Lazar


20. Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody-Drug Conjugates (ADCs)

            Weibing Ding